Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells

Journal of Pineal Research

Volumn 52, Issue 2, 2012, Pages 244-252

  Kim, Ji Hyun ^a   Jeong, Soo Jin ^a   Kim, Bonglee ^a   Yun, Sun Mi ^a   Choi, Do Young ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

apoptosis; cisplatin; heat shock protein 27; melatonin; ovarian cancer; p90 ribosomal S6 kinase

Indexed keywords

CASPASE 3; CISPLATIN; DNA; HEAT SHOCK PROTEIN 27; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; S6 KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DRUG INHIBITION; DRUG POTENTIATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; NICK END LABELING; OVARIAN EPITHELIAL CELL; OVARY; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IN SITU NICK-END LABELING; MELATONIN; OVARIAN NEOPLASMS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

EID: 84856756338     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00935.x     Document Type: Article

References (54)

1. Timmer-Bosscha H, Mulder NH, De Vries EG,. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992; 66: 227-238.
2. Dong J, Su SY, Wang MY, et al., Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 2010; 29: 137.
3. Mcculloch M, See C, Shu XJ, et al., Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006; 24: 419-430. (Pubitemid 46655594)
4. Liu Y, Chen L, He X, et al., Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer 2008; 18: 652-659. (Pubitemid 352020159)
5. Reiter RJ,. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
6. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
7. Cassone VM,. Effects of melatonin on vertebrate circadian systems. Trends Neurosci 1990; 13: 457-464. (Pubitemid 20332799)
8. Reiter RJ, Tan DX, Manchester LC, et al., Melatonin and reproduction revisited. Biol Reprod 2009; 81: 445-456.
9. Tan DX, Manchester LC, Fuentes-Broto L, et al., Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011; 12: 167-188.
10. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al., A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200. (Pubitemid 41558451)
11. Mills E, Wu P, Seely D, et al., Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39: 360-366.
12. Jung-Hynes B, Reiter RJ, Ahmad N,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
13. Shiu SY, Pang B, Tam CW, et al., Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Galpha(s) and Galpha(q) proteins. J Pineal Res 2010; 49: 301-311.
14. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
15. Paradies G, Petrosillo G, Paradies V, et al., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
16. Lissoni P, Barni S, Mandala M, et al., Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688-1692. (Pubitemid 30050641)
17. Fan LL, Sun GP, Wei W, et al., Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 2010; 16: 1473-1481.
18. Casado-Zapico S, Rodriguez-Blanco J, Garcia-Santos G, et al., Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010; 48: 72-80.
19. Reiter RJ, Tan DX, Sainz RM, et al., Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-1321. (Pubitemid 35174175)
20. Frodin M, Gammeltoft S,. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999; 151: 65-77.
21. Clark DE, Errington TM, Smith JA, et al., The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 2005; 65: 3108-3116. (Pubitemid 40524591)
22. Law JH, Habibi G, Hu K, et al., Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
23. Smith JA, Poteet-Smith CE, Xu Y, et al., Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005; 65: 1027-1034. (Pubitemid 40216465)
24. Tan Y, Ruan H, Demeter MR, et al., p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 1999; 274: 34859-34867. (Pubitemid 129509532)
25. Zoubeidi A, Zardan A, Wiedmann RM, et al., Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010; 70: 2307-2317.
26. Ahn Q, Jeong SJ, Lee HJ, et al., Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett 2010; 298: 212-221.
27. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
28. Kim JH, Jeong SJ, Kwon TR, et al., Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011; 16: 696-707.
29. Park S, Lee HJ, Jeong SJ, et al., Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. Food Chem Toxicol 2011; 49: 1367-1372.
30. Han I, Jeong SJ, Lee HJ, et al., Proteomic analysis of mesenchymal stem-like cells derived from ovarian teratoma: potential role of glutathione S-transferase M2 in ovarian teratoma. Proteomics 2011; 11: 352-360.
31. Klongpanichapak S, Phansuwan-Pujito P, Ebadi M, et al., Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. J Pineal Res 2007; 43: 65-73. (Pubitemid 47035223)
32. Oz E, Erbas D, Surucu HS, et al., Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 2006; 282: 31-37. (Pubitemid 43019460)
33. Romero A, Egea J, Garcia AG, et al., Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res 2010; 49: 141-148.
34. Sliwinski T, Rozej W, Morawiec-Bajda A, et al., Protective action of melatonin against oxidative DNA damage: chemical inactivation versus base-excision repair. Mutat Res 2007; 634: 220-227. (Pubitemid 47634011)
35. Camps M, Nichols A, Arkinstall S,. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14: 6-16. (Pubitemid 30051518)
36. Yunos NM, Beale P, Yu JQ, et al., Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res 2011; 31: 1131-1140.
37. Su W, Huang L, Ao Q, et al., Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1alpha. Cancer Lett 2011; 305: 94-99.
38. Choi CH, Lee YY, Song TJ, et al., Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer 2010; 117: 2104-2111.
39. Sainz RM, Mayo JC, Rodriguez C, et al., Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-1426. (Pubitemid 36900523)
40. Shiu SY, Law IC, Lau KW, et al., Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35: 177-182. (Pubitemid 37100395)
41. Cos S, Sanchez-Barcelo EJ,. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 2000; 15: 637-647. (Pubitemid 30218860)
42. Cabrera J, Negrin G, Estevez F, et al., Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49: 45-54.
43. Kikuchi Y, Kita T, Miyauchi M, et al., Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. Gynecol Oncol 1989; 32: 60-64. (Pubitemid 19029869)
44. Bartsch H, Buchberger A, Franz H, et al., Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci 2000; 67: 2953-2960.
45. Hara M, Yoshida M, Nishijima H, et al., Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001; 30: 129-38. (Pubitemid 32245283)
46. Wang ZB, Liu YQ, Cui YF,. Pathways to caspase activation. Cell Biol Int 2005; 29: 489-496.
47. Kothakota S, Azuma T, Reinhard C, et al., Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278: 294-298. (Pubitemid 27450877)
48. Pearson G, Robinson F, Beers Gibson T, et al., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-183. (Pubitemid 32458157)
49. Xia Z, Dickens M, Raingeaud J, et al., Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
50. Eisinger-Mathason TS, Andrade J, Lannigan DA,. RSK in tumorigenesis: connections to steroid signaling. Steroids 2010; 75: 191-202.
51. Kroczynska B, Kaur S, Katsoulidis E, et al., Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)-and ribosomal protein S6K-mediated signals. Mol Cell Biol 2009; 29: 2865-2875.
52. Koh PO,. Melatonin attenuates the cerebral ischemic injury via the MEK/ERK/p90RSK/bad signaling cascade. J Vet Med Sci 2008; 70: 1219-1223.
53. Rocchi P, So A, Kojima S, et al., Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-6602. (Pubitemid 39297919)
54. Krueckl SL, Sikes RA, Edlund NM, et al., Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620-8629. (Pubitemid 39552075)